118 related articles for article (PubMed ID: 33599345)
1. Effect of crocin versus fluoxetine in treatment of mild to moderate obsessive-compulsive disorder: A double blind randomized clinical trial.
Kazemi F; Vosough I; Sepahi S; Mohajeri SA
Hum Psychopharmacol; 2021 Jul; 36(4):e2780. PubMed ID: 33599345
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of transcranial direct current stimulation as add-on therapy to fluoxetine in obsessive-compulsive disorder: a randomized, double-blind, sham-controlled, clinical trial.
Yoosefee S; Amanat M; Salehi M; Mousavi SV; Behzadmanesh J; Safary V; Yoonesi A; Salehi B
BMC Psychiatry; 2020 Nov; 20(1):570. PubMed ID: 33256659
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy assessment of fluoxetine treatment of outpatients with obsessive-compulsive disorder: a preliminary report].
Wandzel L
Psychiatr Pol; 1997; 31(4):429-35. PubMed ID: 9527686
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
Riddle MA; Scahill L; King RA; Hardin MT; Anderson GM; Ort SI; Smith JC; Leckman JF; Cohen DJ
J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1062-9. PubMed ID: 1429406
[TBL] [Abstract][Full Text] [Related]
5. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study.
Bergeron R; Ravindran AV; Chaput Y; Goldner E; Swinson R; van Ameringen MA; Austin C; Hadrava V
J Clin Psychopharmacol; 2002 Apr; 22(2):148-54. PubMed ID: 11910259
[TBL] [Abstract][Full Text] [Related]
6. Reboxetine Combination Therapy With Fluoxetine in Moderate to Severe Obsessive-Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial.
Tilaki EH; Hasanzadeh A; Shalbafan M; Moghaddam HS; Shamabadi A; Boroon M; Akhondzadeh S
Clin Neuropharmacol; 2023 Sep-Oct 01; 46(5):175-180. PubMed ID: 37747999
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of Obsessive-Compulsive Disorder.
Sayyah M; Boostani H; Pakseresht S; Malayeri A
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):362-5. PubMed ID: 20035818
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: Double-blind, randomized, placebo-controlled trial.
Farnia V; Gharehbaghi H; Alikhani M; Almasi A; Golshani S; Tatari F; Davarinejad O; Salemi S; Sadeghi Bahmani D; Holsboer-Trachsler E; Brand S
J Psychiatr Res; 2018 Sep; 104():137-143. PubMed ID: 30044966
[TBL] [Abstract][Full Text] [Related]
9. 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control.
Yousefzadeh F; Sahebolzamani E; Sadri A; Mortezaei A; Aqamolaei A; Mortazavi SH; Shalbafan MR; Ghaffari S; Alikhani R; Mousavi SB; Naderi S; Shamabadi A; Jalilevand S; Akhondzadeh S
Int Clin Psychopharmacol; 2020 Sep; 35(5):254-262. PubMed ID: 32541380
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
Mowla A; Boostani S; Dastgheib SA
J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD).
Alaghband-Rad J; Hakimshooshtary M
Eur Child Adolesc Psychiatry; 2009 Mar; 18(3):131-5. PubMed ID: 19190958
[TBL] [Abstract][Full Text] [Related]
12. Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial.
Talaei A; Hassanpour Moghadam M; Sajadi Tabassi SA; Mohajeri SA
J Affect Disord; 2015 Mar; 174():51-6. PubMed ID: 25484177
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind Randomized Clinical Trial.
Esalatmanesh S; Biuseh M; Noorbala AA; Mostafavi SA; Rezaei F; Mesgarpour B; Mohammadinejad P; Akhondzadeh S
Iran J Psychiatry; 2017 Jul; 12(3):154-162. PubMed ID: 29062366
[No Abstract] [Full Text] [Related]
14. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder.
Tollefson GD; Rampey AH; Potvin JH; Jenike MA; Rush AJ; kominguez RA; Koran LM; Shear MK; Goodman W; Genduso LA
Arch Gen Psychiatry; 1994 Jul; 51(7):559-67. PubMed ID: 8031229
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group.
Montgomery SA; McIntyre A; Osterheider M; Sarteschi P; Zitterl W; Zohar J; Birkett M; Wood AJ
Eur Neuropsychopharmacol; 1993 Jun; 3(2):143-52. PubMed ID: 8364350
[TBL] [Abstract][Full Text] [Related]
16. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.
Geller DA; Hoog SL; Heiligenstein JH; Ricardi RK; Tamura R; Kluszynski S; Jacobson JG;
J Am Acad Child Adolesc Psychiatry; 2001 Jul; 40(7):773-9. PubMed ID: 11437015
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of cognitive behavioral therapy and fluoxetine on sexual function of women with obsessive compulsive disorder: A double-blind randomized controlled trial.
Sabetnejad Z; Assarian F; Omidi A; Najarzadegan MR
Electron Physician; 2016 Nov; 8(11):3156-3163. PubMed ID: 28070247
[TBL] [Abstract][Full Text] [Related]
18. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study.
Li F; Welling MC; Johnson JA; Coughlin C; Mulqueen J; Jakubovski E; Coury S; Landeros-Weisenberger A; Bloch MH
J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):32-37. PubMed ID: 31800306
[No Abstract] [Full Text] [Related]
19. A double-blind trial of fluoxetine in pathologic skin picking.
Simeon D; Stein DJ; Gross S; Islam N; Schmeidler J; Hollander E
J Clin Psychiatry; 1997 Aug; 58(8):341-7. PubMed ID: 9515971
[TBL] [Abstract][Full Text] [Related]
20. Predictors of drug treatment response in obsessive-compulsive disorder.
Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
J Clin Psychiatry; 1995 Aug; 56(8):368-73. PubMed ID: 7635854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
